Versameb moves forward with its lead asset towards clinical development with an Innovative synthetic doggybone DNA technology which increases quality and yield of mRNA therapeutics production Touchlight, a biotechnology company pioneering enzymatic DNA production to enable the genetic medicine revolution, today announces a development and manufacturing pipeline agreement with Versameb AG, an innovative pre-clinical stage […]
Data demonstrates first-in-class potential as a regenerative treatment of Stress Urinary Incontinence Treatment results in muscle regeneration with restored functionality in pre-clinical models Versameb AG (“Versameb”), a pre-clinical stage company focused on discovering and developing innovative RNA-based therapeutics, today announces that its Chief Scientific Officer, Friedrich Metzger will be presenting data on the Company’s mRNA […]
Versameb AG (“Versameb”), a pre-clinical stage company focused on discovering and developing innovative RNA-based therapeutics, today announces that it will be attending Biotech Showcase: The Investor Conference for Innovators on 10-12 January 2022. The Versameb team will be attending virtually. Read more…
